Neurotoxicity	neurotoxicity	O	S_disease
of	of	O	O
halogenated	halogenated	O	O
hydroxyquinolines	hydroxyquinolines	O	O
:	:	O	O
clinical	clinical	O	O
analysis	analysis	O	O
of	of	O	O
cases	cases	O	O
reported	reported	O	O
outside	outside	O	O
Japan	japan	O	O
.	.	O	O

An	an	O	O
analysis	analysis	O	O
is	is	O	O
presented	presented	O	O
of	of	O	O
220	220	O	O
cases	cases	O	O
of	of	O	O
possible	possible	O	O
neurotoxic	neurotoxic	O	S_disease
reactions	reactions	O	O
to	to	O	O
halogenated	halogenated	O	O
hydroxyquinolines	hydroxyquinolines	O	O
reported	reported	O	O
from	from	O	O
outside	outside	O	O
Japan	japan	O	O
.	.	O	O

In	in	O	O
80	80	O	O
cases	cases	O	O
insufficient	insufficient	O	O
information	information	O	O
was	was	O	O
available	available	O	O
for	for	O	O
adequate	adequate	O	O
comment	comment	O	O
and	and	O	O
in	in	O	O
29	29	O	O
a	a	O	O
relationship	relationship	O	O
to	to	O	O
the	the	O	O
administration	administration	O	O
of	of	O	O
clioquinol	clioquinol	O	O
could	could	O	O
be	be	O	O
excluded	excluded	O	O
.	.	O	O

Of	of	O	O
the	the	O	O
remainder	remainder	O	O
,	,	O	O
a	a	O	O
relationship	relationship	O	O
to	to	O	O
clioquinol	clioquinol	O	O
was	was	O	O
considered	considered	O	O
probable	probable	O	O
in	in	O	O
42	42	O	O
and	and	O	O
possible	possible	O	O
in	in	O	O
69	69	O	O
cases	cases	O	O
.	.	O	O

In	in	O	O
six	six	O	O
of	of	O	O
the	the	O	O
probable	probable	O	O
cases	cases	O	O
the	the	O	O
neurological	neurological	O	O
disturbance	disturbance	O	O
consisted	consisted	O	O
of	of	O	O
an	an	O	O
acute	acute	O	O
reversible	reversible	O	O
encephalopathy	encephalopathy	O	S_disease
usually	usually	O	O
related	related	O	O
to	to	O	O
the	the	O	O
ingestion	ingestion	O	O
of	of	O	O
a	a	O	O
high	high	O	O
dose	dose	O	O
of	of	O	O
clioquinol	clioquinol	O	O
over	over	O	O
a	a	O	O
short	short	O	O
period	period	O	O
.	.	O	O

The	the	O	O
most	most	O	O
common	common	O	O
manifestation	manifestation	O	O
,	,	O	O
observed	observed	O	O
in	in	O	O
15	15	O	O
further	further	O	O
cases	cases	O	O
,	,	O	O
was	was	O	O
isolated	isolated	O	O
optic	optic	O	B_disease
atrophy	atrophy	O	S_disease
.	.	O	O

This	this	O	O
was	was	O	O
most	most	O	O
frequently	frequently	O	O
found	found	O	O
in	in	O	O
children	children	O	O
,	,	O	O
many	many	O	O
of	of	O	O
whom	whom	O	O
had	had	O	O
received	received	O	O
clioquinol	clioquinol	O	O
as	as	O	O
treatment	treatment	O	O
for	for	O	O
acrodermatitis	acrodermatitis	O	B_disease
enteropathica	enteropathica	O	I_disease
.	.	O	O

In	in	O	O
the	the	O	O
remaining	remaining	O	O
cases	cases	O	O
,	,	O	O
a	a	O	O
combination	combination	O	O
of	of	O	O
myelopathy	myelopathy	O	O
,	,	O	O
visual	visual	O	O
disturbance	disturbance	O	O
,	,	O	O
and	and	O	O
peripheral	peripheral	O	B_disease
neuropathy	neuropathy	O	S_disease
was	was	O	O
the	the	O	O
most	most	O	O
common	common	O	O
manifestation	manifestation	O	O
.	.	O	O

Isolated	isolated	O	O
myelopathy	myelopathy	O	O
or	or	O	O
peripheral	peripheral	O	B_disease
neuropathy	neuropathy	O	S_disease
,	,	O	O
or	or	O	O
these	these	O	O
manifestations	manifestations	O	O
occurring	occurring	O	O
together	together	O	O
,	,	O	O
were	were	O	O
infrequent	infrequent	O	O
.	.	O	O

The	the	O	O
onset	onset	O	O
of	of	O	O
all	all	O	O
manifestations	manifestations	O	O
(	(	O	O
except	except	O	O
toxic	toxic	O	O
encephalopathy	encephalopathy	O	S_disease
)	)	O	O
was	was	O	O
usually	usually	O	O
subacute	subacute	O	O
,	,	O	O
with	with	O	O
subsequent	subsequent	O	O
partial	partial	O	O
recovery	recovery	O	O
.	.	O	O

Older	older	O	O
subjects	subjects	O	O
tended	tended	O	O
to	to	O	O
display	display	O	O
more	more	O	O
side	side	O	O
effects	effects	O	O
.	.	O	O

The	the	O	O
full	full	O	O
syndrome	syndrome	O	O
of	of	O	O
subacute	subacute	O	O
myelo-optic	myelo-optic	O	O
neuropathy	neuropathy	O	S_disease
was	was	O	O
more	more	O	O
frequent	frequent	O	O
in	in	O	O
women	women	O	O
,	,	O	O
but	but	O	O
they	they	O	O
tended	tended	O	O
to	to	O	O
have	have	O	O
taken	taken	O	O
greater	greater	O	O
quantities	quantities	O	O
of	of	O	O
the	the	O	O
drug	drug	O	O
.	.	O	O

